申请人:LG CHEM, LTD.
公开号:EP3778577A1
公开(公告)日:2021-02-17
The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia, etc. comprising the compound or pharmaceutically acceptable salt, and a method for preventing or treating metabolic disease using the above novel compound. The compound of the present invention has excellent inhibitory activity against enteropeptidase, and thus is not absorbed into the body, but are excreted outside the body. However, since not only fat but also protein are discharged together, it has few side effects such as fat stools and acts only in the gastrointestinal tract, so it has few side effects such as depression, and is very useful as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.
本发明涉及一种具有肠肽酶抑制活性的新型化合物、其药学上可接受的盐、包含该化合物或药学上可接受的盐的用于预防和治疗肥胖、糖尿病或高脂血症等代谢性疾病的药物组合物,以及使用上述新型化合物预防或治疗代谢性疾病的方法。本发明的化合物对肠肽酶有很好的抑制活性,因此不会被人体吸收,而是排出体外。然而,由于不仅脂肪,而且蛋白质也一起排出体外,因此它很少有脂肪便等副作用,而且只作用于胃肠道,所以很少有抑郁等副作用,作为肥胖症、糖尿病和高脂血症等各种代谢疾病的治疗或预防药物非常有用。